Dr Josh Levine, is the product team lead for Berobenatide, a novel GLP-1 receptor agonist in phase 3 testing at Pfizer.  He received his MD and PhD from Columbia University.  He then went on to complete his clinical training in Internal Medicine and Endocrinology at Northwestern University.  Josh was on faculty at Northwestern and shortly afterwards joined Eli Lilly to be the US launch lead for Mounjaro.  He joined Pfizer to run the phase 3 clinical trials in obesity including his current position on Berobenatide.

In addition to his work at Pfizer, Josh maintains a clinical practice at Montefiore Medical Center in the Bronx seeing patients with endocrinology issues.

Josh currently lives in Scarsdale NY with his wife Rebecca and children Jamie and Elizabeth.